Mechanisms of altered vagal control in heart failure: Influence of muscarinic receptors and acetylcholinesterase activity

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 4 54-4, 2003, Pages

  Dunlap, Mark E ^a,b   Bibevski, Steve ^b   Rosenberry, Terrone L ^c   Ernsberger, Paul ^b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Autonomic; Cholinergic; Parasympathetic

Indexed keywords

ACETYLCHOLINESTERASE; ATROPINE; BETHANECHOL; MUSCARINIC RECEPTOR; NEOSTIGMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DOG; ELECTROSTIMULATION; ENZYME ACTIVITY; HEART FAILURE; HEART PACING; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RR INTERVAL; SINUS NODE; VAGUS NERVE STIMULATION; VAGUS TONE;

EID: 0141565362     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01051.2002     Document Type: Article

References (48)

1. Bibevski S and Dunlap ME. Ganglionic mechanisms contribute to diminished vagal control in heart failure. Circulation 99: 2958-2963, 1999.
2. Bohm M, Gierschick P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, and Erdmann E. Increase of Gi-alpha in human hearts with dilated but not ischaemic cardiomyopathy. Circulation 82: 1249-1265, 1990.
3. Böhm M, Ungerer M, and Erdmann E. Beta adrenoceptors and m-cholinoceptors in myocardium of hearts with coronary artery disease or idiopathic dilated cardiomyopathy removed at cardiac transplantation. Am J Cardiol 66: 880-882, 1990.
4. Casadei B, Pipilis A, Sessa F, Conway J, and Sleight P. Low doses of scopolamine increase cardiac vagal tone in the acute phase of myocardial infarction. Circulation 88: 353-357, 1993.
5. Creazzo TL and Wrenn RW. Increased muscarinic receptor binding in heart membranes by an inhibitor of protein kinase C. FEBS Lett 242: 175-177, 1988.
6. Dibner-Dunlap ME, Eckberg DL, Magid NM, and Cintron-Trevino NM The long-term increase of baseline and reflexly augmented levels of human vagal-cardiac nervous activity induced by scopolamine. Circulation 71: 797-804, 1985.
7. Dibner-Dunlap ME and Thames MD. Baroreflex control of renal sympathetic nerve activity is preserved in heart failure despite reduced arterial baroreceptor sensitivity. Circ Res 65: 1526-1535, 1989.
8. Dibner-Dunlap ME and Thames MD. A simplified technique for the production of heart failure in the dog by rapid ventricular pacing. Am J Med Sci 300: 288-290, 1990.
9. Dibner-Dunlap ME and Thames MD. Control of sympathetic nerve activity by vagal mechanoreflexes is blunted in heart failure. Circulation 86: 1929-1934, 1992.
10. Eckberg DL, Drabinsky M, and Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 285: 877-883, 1971.
11. Engel AG, Lambert EH, and Gomez MR. A new myasthenic syndrome with endplate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release. Ann Neurol 1: 315-330, 1977.
12. Ernsberger P, Arneric SP, Arango V, and Reis DJ. Quantitative distribution of muscarinic receptors and choline acetyltransferase in rat medulla: examination of transmitter-receptor mismatch. Brain Res 452: 336-344, 1988.
13. Ernsberger P and Nelson DO. Refeeding hypertension in dietary obesity. Am J Physiol Regul Integr Comp Physiol 254: R47-R55, 1988.
14. Eschenhagen T, Mede U, Nose M, Schmitz W, Scholz H, Haverich A, Hirt S, Doring V, Kalmar P, Hoppner W, and Seitz HJ. Increased messenger RNA level of the inhibitory G-protein alpha subunit Gi-alpha-2 in human end stage heart failure. Circ Res 70: 688-696, 1992.
15. Feldman AM, Cates AE, Veazey W, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, and Van Dop C. Increase in the 40,000 mol. Wt Pertussis toxin substrate (G-protein) in the failing human heart. J Clin Invest 82: 189-197, 1988.
16. Fu LX, Feng QP, Liang QM, Sun XY, Hedner T, Hoebeke J, and Hjalmarson A. Hypersensitivity of Gi protein mediated muscarinic receptor adenylyl cyclase in chronic ischaemic heart failure in the rat. Cardiovasc Res 27: 2065-2070, 1993.
17. Gilman AG, Goodman LS, and Gilman A. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: Macmillan, 1980.
18. Jo SA, Higgins DM, and Berman HA. Regulation of acetylcholinesterase in avian heart. Studies on ontogeny and influence of vagotomy. Circ Res 70: 633-643, 1992.
19. Katona PG and Jih F. Respiratory sinus arrhythmia: noninvasive measure of parasympathetic cardiac control. J Appl Physiol 39: 801-805, 1975.
20. Kinugawa T and Dibner-Dunlap ME. Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure. Am J Physiol Regul Integr Comp Physiol 268: R317-R323, 1995.
21. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ, and The Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 59: 256-262, 1987.
22. Levey MS and Jacob MH. Changes in the regulatory effects of cell-cell interactions on neuronal AChR subunit transcript levels after synapse formation. J Neurosci 16: 6878-6885, 1996.
23. McKinney M and Coyle JT. Regulation of neocortical muscarinic receptors: effects of drug treatment and lesions. J Neurosci 2: 97-105, 1982.
24. McPherson GA. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods 14: 213-228, 1985.
25. 2-muscarinic receptors in the human right atrium. Br J Pharmacol 101: 363-369, 1990.
26. Munson PJ and Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand binding systems. Anal Biochem 107: 220-239, 1980.
27. i-proteins in heart failure. Lancet 2: 936-937, 1988.
28. Newton GE, Parker AB, Landzberg JS, Colucci WS, and Parker JD. Muscarinic receptor modulation of basal and beta-adrenergic stimulated function of the failing human left ventricle. J Clin Invest 98: 2756-2763, 1996.
29. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83: 346-356, 1977.
30. Randall WC, Jones SB, Lipsius SL, and Rozanski GJ. Subsidiary atrial pacemakers and their neural control. In: Nervous Control of Cardiovascular Function, edited by Randall WC. New York: Oxford University Press, 1984, p. 199-224.
31. Riddles PW, Blakeley RL, and Zerner B. Ellmans's reagent: 5,5′-dithiobis(2-nitrobenzoic acid)-a reexamination. Anal Biochem 94: 75-81, 1979.
32. Robberecht P, Waelbroeck M, Claeys M, Huu AN, Chatelain P, and Christophe J. Rat cardiac muscarinic receptors. II Influence of thyroid status and cardiac hypertrophy. Mol Pharmacol 21: 589-593, 1982.
33. Rosenberry TL. Acetylcholinesterase. Adv Enzymol Relat Areas Mol Biol 43: 103-218, 1975.
34. Rosenberry TL and Scoggin DM. Structure of human erythrocyte acetylcholinesterase. Characterization of intersubunit disulfide bonding and detergent interaction. J Biol Chem 259: 5643-5652, 1984.
35. Roskoski R Jr, Reinhardt RR, Enseleit W, Johnson WD, and Cook PF. Cardiac cholinergic muscarinic receptors: change in multiple affinity forms with downregulation. J Pharmacol Exp Ther 232: 754-759, 1985.
36. Schimerlik MI. Structure and regulation of muscarinic receptors. Annu Rev Physiol 51: 217-227, 1989.
37. Shepherd JT and Vanhoutte PM. The Human Cardiovascular System. New York: Raven, 1979.
38. Smith DC, Priola DV, and Anagnostelis C. Comparison of in vivo and in vitro cholinergic responses of normal and denervated canine hearts. J Pharmacol Exp Ther 235: 37-44, 1985.
39. Stambler BS, Fenelon G, Shepard RK, Clemo HF, and Guiraudon CM. Characterization of sustained atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol 14, 499-507, 2003.
40. Taylor P. Cholinergic agonists. In: The Pharmacological Basis of Therapeutics, edited by Goodman LS and Gilman A. New York: Pergamon, 1990, p. 122-130.
41. Vatner DE, Sato N, Galper JB, and Vatner SF. Physiological and biochemical evidence for coordinate increase in muscarinic receptor and Gi during pacing induced heart failure. Circulation 94: 102-107, 1996.
42. Vatner DE, Lee DL, Schwarz KR, Longabaugh JP, Fujii AM, Vatner SF, and Homcy CJ. Impaired cardiac muscarinic receptor function in dogs with heart failure. J Clin Invest 81: 1836-1842, 1988.
43. Wang W, Chen JS, and Zucker IH. Carotid sinus baroreceptor sensitivity in experimental heart failure [see comments]. Circulation 81: 1959-1966, 1990.
44. 2-cholinoceptors. Naunyn Schmiedebergs Arch Pharmacol 338: 19-27, 1988.
45. White CW. Abnormalities in baroreflex control of heart rate in canine heart failure. Am J Physiol Heart Circ Physiol 240: H793-H799, 1981.
46. Wiedmer T, Di Francesco C, and Brodbeck U. Effect of amphiphiles on structure and activity of human erythrocyte membrane acetylcholinesterase. Eur J Biochem 102: 59-64, 1979.
47. Wise BC, Shoji M, and Kuo JF. Decrease or increase in cardiac muscarinic cholinergic receptor number in rats treated with methacholine or atropine. Biochem Biophys Res Commun 92: 1136-1142, 1980.
48. Yuan BX, Ardell JL, Hopkins DA, Losier AM, and Armour JA. Gross and microscopic anatomy of the canine intrinsic cardiac nervous system. Anat Rec 239: 75-87, 1994.